81 results about "Vector vaccine" patented technology

The invention provides application of a porcine parainfluenza virus type 5 as an expression vector, and belongs to the technical field of biological vaccines. According to the invention, a PIV5 strain separated from diarrhea pigs in Jiangsu Province in China is utilized to construct PIV5 virus infectious clone. The eGFP gene is inserted into a PIV5 infectious cloned virus genome, the recombinant PIV5 virus capable of expressing the green fluorescent protein is successfully rescued, and when the eGFP gene is inserted into a P / M gene spacer region, the expression quantity is the highest, which indicates that an exogenous gene expression cassette can influence the expression level of an exogenous gene, and the P / M gene spacer region is the optimal site for inserting the exogenous gene, so that the recombinant PIV5 virus can be successfully rescued. And a solid foundation is laid for developing a vector vaccine by utilizing the swine PIV5. The porcine parainfluenza virus type 5 can be used as an expression vector to express foreign proteins, can also be used for preparing oral vaccines, and can relieve the stress reaction of pigs in the immune process.

The present invention relates to the field of animal health. Particularly, the present invention relates to an attenuated Duck Enteritis Virus (DEV). More particularly, the present invention relates to an attenuated DEV that shows no or a reduced pathogenicity in duck and chicken. Furthermore, the present invention relates to a composition, comprising the attenuated DEV of the invention as vector-vaccine for poultry, and the use thereof.

The invention provides a recombinant HSV-1 vector, oncolytic HSV-1 and application of the oncolytic HSV-1, and belongs to the technical field of viral vectors. According to the recombinant HSV-1 vector provided by the invention, nucleotides at the 117014 site to the 132565 site and nucleotides at the 145316 site to the 145585 site in an HSV-1 genome are deleted. The recombinant HSV-1 vector provided by the invention is high in safety, can be copied in mammalian cells and carry a plurality of exogenous genes, has the advantages of wide host range, high infection efficiency, large capacity, easiness in preparation and sustainable expression of the carried exogenous genes, and can be applied to the fields of tumor treatment, gene therapy and virus vector vaccines. The oncolytic HSV-1 provided by the invention is high in safety, retains the replication ability in mammalian cells, has a remarkable oncolytic effect, and can induce an organism to generate tumor immune response so as to play a tumor inhibition role.

The invention belongs to the technical field of biology, and particularly relates to an immunogenic peptide fragment aiming at a human sphingosine 1-phosphate receptor 2 and application of the immunogenic peptide fragment. The amino acid sequence of the immunogenic peptide fragment is SEQ ID No.1. The immunogenic vector vaccine aiming at the human sphingosine 1-phosphate receptor 2 is prepared by coupling the immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 and a vector, and the vector is Q beta-2aa bacteriophage virus-like particle protein. According to the invention, the preferentially designed immunogenic peptide fragment of the human sphingosine 1-phosphate receptor 2 is coupled with the Qbeta-2aa bacteriophage virus-like particle protein carrier to successfully prepare the carrier vaccine. The immunogenic vector vaccine can be used for preparing drugs for preventing and treating abdominal aortic aneurysm.

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The present invention relates to an atomized inhalable vaccine formulation and a preparation method therefor. The formulation comprises an active ingredient and auxiliary materials. The active ingredient is an antigen protein-expressing recombinant human replication-defective adenovirus at a low concentration. The auxiliary materials include a buffer, a protectant, a stabilizer, a surfactant, and an osmotic pressure regulator. The atomized inhalable vaccine formulation of the present invention can retain the good stability of a human replication-defective adenovirus vector vaccine formulation.

The application relates to the technical field of biological medicine, and particularly discloses a fish rhabdovirus recombinant adenovirus vector vaccine and a preparation method and application thereof. The recombinant adenovirus vaccine carrying the M gene of the SCRV virus is prepared by using a replication-defective recombinant adenovirus vector, and the preparation method comprises the following steps: mandarin fish rhabdovirus M gene cloning, construction of a Pshuttle-CMV-ECMV vector with a target gene SCRV-M, obtaining of a SCRV-M recombinant adenovirus plasmid, screening of the SCRV-M recombinant adenovirus, and preparation of the SCRV-M recombinant adenovirus vaccine. The SCRV-M recombinant adenovirus vaccine prepared by the application can be used for immunoprophylaxis of SCRV virus infection in the juvenile fish stage through a soaking mode, the SCRV-M recombinant adenovirus vaccine has passed an animal safety test, and has a wide application prospect in the prevention and control of fish rhabdovirus.

The invention belongs to the technical field of biological medicine, and particularly relates to a rabies virus G protein carrier, a rabies virus vaccine and a preparation method and application of the rabies virus G protein carrier and the rabies virus vaccine. The rabies virus G protein vector pscAAV-G is obtained by inserting a coding gene of rabies virus G protein into a coding region between inverted terminal repetitive sequences at two ends of a double-chain adeno-associated virus vector, so that the problem of expression delay of single-chain AAV (ssAAV) is solved, and rapid and efficient expression of the rabies virus G protein is realized; furthermore, an endogenous nucleic acid adjuvant is embedded into a non-coding region of the pscAAV-G, so that the rabies virus G protein carrier pscAAV-G-Adj is prepared, and Th1 type immune response is remarkably improved. According to a rabies virus vaccine prepared by using the rabies virus G protein carrier, the antigen expression efficiency and immunogenicity of an AAV carrier vaccine are remarkably improved, long-acting protection of single inoculation is realized, and the defects that an existing rabies vaccine is short in immune cycle and needs to be inoculated for multiple times are overcome.

The invention discloses a recombinant vector for expressing varIBDV VP2 gene Meg Gene-deficient Marek's disease virus strain and its construction method and application. Meg The gene-deficient Marek's disease virus strain is obtained by using recombinant cloning technology to insert the gene fragment CMV-VP2 containing the CMV promoter sequence, varIBDV VP2 gene and terminator sequence into the Meg The gene-deleted Marek's disease virus strain rMSΔMeq US2 gene was obtained by replacing the nucleotide sequence between positions 156501-157116 of the rMSΔMeq genome, and was named rMDV-varVP2. Studies have shown that the recombinant obtained by the present invention Meg The gene-deficient Marek's disease virus rMDV-varVP2 has the same in vitro replication ability and good genetic stability as the parent virus rMSΔMeq strain, and rMDV-varVP2 can provide good protection against IBDV mutants after immunizing chickens. The present invention provides a technical means for the development of a recombinant MDV live vector vaccine.

The invention relates to the field of aquaculture, in particular to a preparation method and application of a recombinant live vector vaccine for infectious hematopoietic necrosis of fish. In order to solve the problem of prevention and control of the infectious hematopoietic necrosis of the fish in the aquatic product industry, a replication-defective adenovirus type 5 is selected as a target gene expression vector to construct a recombinant adenovirus vector comprising a glycoprotein gene and a nucleoprotein gene of the infectious hematopoietic necrosis virus of the fish, and a recombinant virus is obtained; the safe and effective recombinant live vector vaccine for the infectious hematopoietic necrosis of the fish is created. According to the vaccine, immunization is carried out on fishes in a soaking or bait feeding mode, the total CPM of the fishes immunized by the vaccine is 6.67%, and the total CPM of the fishes in a non-immunized control group is 94.00%. In addition, the RPS of the vaccination group fish and the RPS of the empty vector control group fish are 92.90% and 9.22% respectively. The method is at a leading level in the field of fish biological medicines at present and has remarkable creativity.

The invention relates to the field of animal health. In particular, the present invention relates to a composition comprising a modified duck enteritis virus (DEV) comprising and capable of expressing a heterologous polynucleotide encoding an antigen of a chicken pathogen. In addition, the present invention relates to a composition comprising the modified DEV as a chicken vector vaccine and uses thereof. More particularly, the present invention relates to a vaccine composition against chicken pathogens comprising a modified DEV that does not exhibit or exhibits reduced pathogenicity in chicken.

The invention discloses a Brucella vaccine of recombinant adenovirus based on BP26 and IFNG and application, and belongs to the technical field of biological medicine. In order to develop a safe and effective brucella recombinant adenovirus vector vaccine, a brucella immunodominance antigen is designed through a genetic engineering technology, a recombinant adenovirus of an antigen-coupled molecular adjuvant IFN-gamma is constructed, and the constructed recombinant adenovirus is identified through PCR, WB, an electron microscope and the like. And the immune stimulation capability and the protective efficacy of the brucella recombinant adenovirus vector vaccine are evaluated by verifying the cellular immune response level and the humoral immune response level induced by the vaccine at a mouse level and the challenge protection efficiency, so that a foundation is laid for research and development of a brucella recombinant adenovirus candidate vaccine.

The present invention relates to a vaccine formulation. An effective ingredient is a recombinant chimpanzee adenovirus expressing an antigen protein, and adjuvants are ethanol and glycerol. The present formulation has no animal-derived ingredient and has high safety. The formulation can maintain good stability of a chimpanzee adenoviral vector vaccine liquid formulation. The vaccine formulation can be stably stored for more than 12 months at 2-8°C, the abnormal toxicity test of the vaccine formulation satisfies the standards, and the vaccine formulation is safe to use. The vaccine formulation can be used as a liquid injection and an atomized inhalation formulation at the same time.

The invention provides an individualized mRNA composition, a carrier, an mRNA vaccine and application thereof, and belongs to the technical field of biological vaccines. Wherein the individualized mRNA composition comprises at least one neoantigen mRNA encoding a tumor neoantigen and at least one associated antigen mRNA encoding a tumor associated antigen. According to the present invention, the new antigen mRNA and the related antigen mRNA are combined to obtain the individualized vaccine material having the high tumor killing biological activity characteristic, such that the targeting killing ability of the tumor specific T cell is increased while the immune system activation progress is accelerated, the human body immune response can be improved, and the possible recurrence in the subsequent process can be prevented.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.

The invention relates to the technical field of biological medicines, and particularly discloses a fish rhabdovirus recombinant adenovirus vector vaccine as well as a preparation method and application thereof. The replication-defective recombinant adenovirus vector is utilized to prepare the recombinant adenovirus vaccine carrying the M gene of the SCRV virus. The preparation method comprises the following steps: cloning the M gene of the mandarin fish rhabdovirus, constructing a Pshuttle-CMV-ECMV vector with a target gene SCRV-M, obtaining an SCRV-M recombinant adenovirus plasmid, screening to obtain the SCRV-M recombinant adenovirus, and preparing the SCRV-M recombinant adenovirus vaccine. The prepared SCRV-M recombinant adenovirus vaccine can be used for immunizing and preventing SCRV virus infection in a juvenile fish stage in a soaking manner, and the SCRV-M recombinant adenovirus vaccine has a wide application prospect in the aspect of prevention and control of fish rhabdovirus after being subjected to an animal safety test.

The present invention relates to the field of (vector) vaccines, and in particular to canine distemper virus (CDV) vectors comprising a heterologous nucleotide sequence encoding a porcine epidemic diarrhea virus (PEDV) antigen. The PEDV antigen is preferably the PEDV spike (S) protein. The viral vectors of the present invention can be used to produce immunogenic compositions or vaccines for intranasal immunization of sows and thereby protecting piglets suckled by such sows against clinical signs associated with PEDV infection.

The present invention relates to the field of animal health. Particularly, the present invention relates to a modified Duck Enteritis Virus (DEV). More particularly, the present invention relates to a modified DEV that shows no or reduced pathogenicity in chicken. Furthermore, the present invention relates to a composition, comprising the modified DEV of the invention as vector-vaccine for chicken, and the use thereof.

The invention belongs to the technical field of biological medicines, and particularly relates to a lactic acid bacteria live vector vaccine for preventing and treating brucellosis and a preparation method of the lactic acid bacteria live vector vaccine. The lactic acid bacteria live vector vaccine is obtained by transferring expression vectors for expressing Brucella omp19 protein and BvrR protein into lactic acid bacteria, and the lactic acid bacteria are lactobacillus cavings. The lactobacillus live vector vaccine for preventing and treating brucellosis is constructed by taking brucella omp19 protein and BvrR protein as immunogens and lactic acid bacteria as an antigen transfer vector, and the safety is good. After the vaccine is used for immunizing mice, the mice can obtain a higher antibody level, the duration is long, brucella infection is effectively inhibited, meanwhile, the production process of the vaccine is simplified, and the vaccine has a good application prospect.

The invention discloses a vector system for packaging a recombinant poxvirus, the vector system comprises a first plasmid, a second plasmid, a third plasmid, a fourth plasmid and a fifth plasmid which respectively carry five sections which are sequentially segmented on the basis of a full-length genome of the poxvirus, the fifth plasmid carries a reverse terminal repeat (RITR) fragment and an LITR fragment of the genome of the poxvirus, and the RITR fragment and the LITR fragment are sequentially segmented on the basis of the full-length genome of the poxvirus. The two ends of each plasmid are provided with overlapping fragments which are subjected to homologous recombination with adjacent plasmids, the 5'end of the first plasmid is adjacent to the 3 'end of the fifth plasmid, and the 3' end of the fourth plasmid is adjacent to the 5 'end of the fifth plasmid. The invention also discloses a method for packaging a recombinant poxvirus by using the recombinant poxvirus vector system and application of the recombinant poxvirus vector system in preparation of a poxvirus vector vaccine, and the recombinant poxvirus has the effects of large loading capacity and strong immune excitation effect.

The invention provides a nucleotide chain for expressing Omicro BA.1 spike protein, a virus and a vaccine, and belongs to the technical field of viral vaccines, the nucleotide chain or the virus comprises a nucleotide sequence as shown in SEQ ID NO.1, on the premise that an expression protein main body is still novel coronavirus BA.1 variant spike protein, the nucleotide sequence is a nucleotide sequence as shown in SEQ ID NO.1, and the nucleotide sequence is a nucleotide sequence as shown in SEQ ID NO.2. A recombinant virus vector vaccine prepared from a nucleotide sequence after experience optimization can effectively stimulate an organism to generate a binding antibody, a neutralizing antibody and cellular immune response aiming at BA.1 variant virus after immunization, and has good immunogenicity.

The present invention discloses an immunogenic peptide segment for human β1-adrenergic receptor and its application, wherein the amino acid sequence of the immunogenic peptide segment is DEARRCYND, as shown in SEQ ID NO.1. The immunogenic vector vaccine for human β1-adrenergic receptor is prepared by coupling the above-mentioned immunogenic peptide segment of human β1-adrenergic receptor with a carrier, and the carrier is Qβ-2aa bacteriophage virus-like particle protein. The present invention successfully couples the preferentially designed immunogenic peptide segment of human β1-adrenergic receptor with the Qβ-2aa bacteriophage virus-like particle protein carrier to prepare a vector vaccine. The immunogenic vector vaccine can be used to prepare drugs for treating hypertension and improving cardiac remodeling after myocardial infarction.

The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.

The present invention provides a bovine parainfluenza virus type 3 and bovine viral diarrhea virus bivalent adenovirus vector vaccine, prepared by cloning the BPIV3C F gene and the BVDV-1E2 gene into a replication-deficient human adenovirus type 5 vector. The BPIV3C F gene sequence is shown in SEQ ID No. 1, and the BVDV-1E2 gene sequence is shown in SEQ ID No. 2. The bivalent vaccine can stimulate the body to produce strong cellular and humoral immunity, with good immune efficacy and high safety.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The invention discloses a canine distemper virus envelope glycoprotein chimeric recombinant Newcastle disease virus as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The CDV F extracellular region chimeric recombinant Newcastle disease virus rNDV-cF and the CDV H protein extracellular region chimeric recombinant Newcastle disease virus rNDV-cH are successfully constructed, the immunogenicity of the recombinant viruses is improved, the CDV F and the CDV H are better packaged to the surface of the NDV, and the recombinant viruses have good genetic stability. After the rNDV-cF and the rNDV-cH are inactivated, an adjuvant is supplemented for independent immunization or combined immunization of mice and dogs, the result shows that all immunization groups can induce the body to generate good humoral immune response, and the rNDV-cH inactivated vaccine and combined immunization have equivalent immune effect, and have good protective effect on dogs attacked by CDV virulent strains; and an important material basis is laid for research and development of novel canine distemper carrier vaccines.

The invention relates to the technical field of mucosal immunity and immunogenicity collaborative optimization, in particular to a preparation method of a mucosal immune type mycoplasma bovis live vector vaccine, attenuated mycoplasma bovis is used as a vector, an inducer X containing an FRET modified nucleic acid aptamer is combined with CRISPR-Cas12a for modification, a virulence gene is knocked out, and a mucosal targeting gene fused with CTB is inserted; carrying out deep codon optimization on the antigen gene, fusing the antigen gene with the glycosylation immunopotentiation peptide, and carrying out novel enzyme digestion connection to construct a recombinant vector; and intelligently fermenting in an improved culture medium, centrifuging, resuspending by using a special protective agent, and freeze-drying to obtain the vaccine. According to the preparation method, the mucous membrane targeting and immunogenicity of the vaccine are improved, and the production process is optimized; mucosal immunity can be quickly stimulated, various immune reactions are activated, the vaccine activity and quality are guaranteed, and the mycoplasmosis bovis is efficiently prevented.

The application discloses a single-chain circular DNA virus GyH1 recombinant polyepitope adenovirus vector vaccine and application thereof, and belongs to the technical field of vaccines.The antigen epitopes of GyH1 VP1, VP2 and VP3 proteins are screened through an online bioinformation analysis server, the antigen epitopes are connected by using a linker to construct a polyepitope vaccine GyMEV, and the nucleotide sequence of the GyMEV is obtained through reverse translation and codon optimization.The antigen polypeptide GyMEV nucleotide sequence is cloned into a plasmid vector pMD19-T through artificial synthesis, the GyMEV is directionally cloned into a linearized adenovirus vector by using seamless cloning technology to obtain a recombinant adenovirus plasmid rAd5-GyMEV, and the recombinant plasmid is transfected into HEK 293 cells to obtain the recombinant polyepitope adenovirus vector vaccine GyMEV.The results show that the GyMEV can more effectively stimulate the immune response of the body and has stronger protection.The vaccine also has the safety of a subunit vaccine and can adopt various immunization modes, can stimulate the immune response of the body in all directions, and thus has a wide development and application prospect.

The invention provides a microbial carrier vaccine, a preparation method thereof and a vaccine composition. A microbial carrier vaccine for antigen delivery with an enteric microbial delivery system is provided, and the enteric microbial delivery system is selected from at least one of a bacteriophage delivery system (e.g., Klebsiella pneumoniae bacteriophage), an Escherichia coli delivery system (e.g., Klebsiella pneumoniae bacteriophage), and an antigen delivery system (e.g., Klebsiella pneumoniae bacteriophage). Escherichia coli S17-1 lambda pi) or a conjugation delivery system of Escherichia coli and intestinal symbiotic bacteria. The microbial carrier vaccine is a vaccine platform developed based on intestinal microorganisms, after the vaccine enters a body, intestinal symbiotic bacteria can be subjected to in-situ editing, so that the intestinal symbiotic bacteria can continuously generate antigens to be applied to the body, the body can be continuously stimulated to generate antibodies, and the continuous protection effect is achieved.